Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in Hormone Refractory Prostate Cancer
NCT00433446Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Apr 2007
- Primary completion
- May 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siltuximab in metastatic castration-resistant prostate cancer (mCRPC), sponsored by SWOG Cancer Research Network. Started Apr 2007; status: completed.
02
Drugs
siltuximab
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00433446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00433446.